Bionano Genomics (NASDAQ:BNGO – Get Free Report)‘s stock had its “sector perform” rating reiterated by Scotiabank in a research note issued on Wednesday, Benzinga reports. They currently have a $1.00 price objective on the stock, down from their prior price objective of $6.00. Scotiabank’s target price indicates a potential upside of 106.95% from the company’s current price.
Separately, BTIG Research dropped their price target on Bionano Genomics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Thursday, May 16th.
Read Our Latest Stock Report on Bionano Genomics
Bionano Genomics Trading Up 1.0 %
Institutional Investors Weigh In On Bionano Genomics
Large investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC acquired a new position in shares of Bionano Genomics in the 2nd quarter valued at approximately $1,138,000. GSA Capital Partners LLP lifted its stake in Bionano Genomics by 532.7% during the first quarter. GSA Capital Partners LLP now owns 549,789 shares of the company’s stock worth $610,000 after purchasing an additional 462,887 shares during the last quarter. Cetera Advisors LLC acquired a new stake in shares of Bionano Genomics in the 1st quarter valued at $163,000. Quadrature Capital Ltd bought a new position in shares of Bionano Genomics in the 4th quarter valued at $209,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Bionano Genomics by 123.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after buying an additional 38,900 shares in the last quarter. Institutional investors and hedge funds own 11.35% of the company’s stock.
About Bionano Genomics
Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.
Featured Articles
- Five stocks we like better than Bionano Genomics
- What Are the FAANG Stocks and Are They Good Investments?
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- Energy and Oil Stocks Explained
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Top Biotech Stocks: Exploring Innovation Opportunities
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.